Oncolytic virotherapy is a promising strategy for reducing tumor burden through selective virus replication in rapidly proliferating cells. However, the lysis of slowly replicating cancer stem cells (CSCs), which maintain neoplastic clonality, is relatively modest and the potential contribution of programmed cell death pathways to oncolytic activity is still poorly understood. We show that the oncolytic virus DPK lyses CSC-enriched breast cancer and melanoma 3D spheroid cultures at low titers (0.1 pfu/cell) without resistance development and it inhibits the 3D growth potential (spheroids and agarose colonies) of melanoma and breast cancer cells. DPK induces calpain activation in both melanoma and breast cancer 3D cultures as determined by the loss of the p28 regulatory subunit, and 3D growth is restored by treatment with the calpain inhibitor PD150606. In melanoma, DPK infection also induces light chain 3 (LC3)-II accumulation and p62/SQSTM1 clearance, both markers of autophagy, and 3D growth is restored by treatment with the autophagy inhibitor chloroquine (CQ). However, expression of the autophagy-required protein Atg5 is not altered and CQ does not restore p62/SQSTM1 expression, suggesting that the CQ effect may be autophagy-independent. PD150606 restores expression of p62/SQSTM1 in DPK-infected melanoma cultures, suggesting that calpain activation induces anti-tumor activity through p62/SQSTM1 clearance.
INTRODUCTION
Oncolytic virotherapy is an innovative, targeted strategy designed to reduce tumor burden through selective virus replication in tumor cells and the generation of infectious progeny that spreads throughout the tumor mass. Platforms have been developed from virtually all the virus families and they have their respective advantages and disadvantages. However, clinical efficacy is modest. 1 This was attributed to low levels of virus replication resulting from the deletions used to achieve tumor selectivity, the induction of antiviral immunity and the failure to effectively eradicate cancer stem cells (CSCs), which are believed to initiate tumor formation. [1] [2] [3] [4] From a clinical perspective, CSC eradication is crucial, but direct studies of CSC lysis are relatively scant. Evolving complexities include the recent recognition that tumors can harbor multiple phenotypically and/or genetically distinct CSCs and that the CSC phenotype can vary substantially between patients, 5, 6 suggesting that oncolytic efficacy could differ for distinct tumor cell types and/or oncolytic viruses.
The oncolytic herpes simplex viruses (oHSV) are primarily based on HSV-1 and are deleted in ICP34.5 and the large subunit of ribonucleotide reductase (R1). Tumor selectivity is due to the increased ribonucleotide reductase activity in tumor as compared with normal cells and the reduced activity of the ICP34.5 target double-stranded RNA-dependent protein kinase. 7 oHSV may also be deleted in ICP47, which is responsible for immune evasion, and/or be armed with a proinflammatory cytokine gene. 8 An oHSV armed with the cytokine granulocyte macrophage colony stimulating factor, known as talimogene laherparepvec, showed promise in a recent clinical study on metastatic melanoma. 9 Another oHSV deleted in R1, ICP34.5 and ICP47 (G47D) lysed human glioblastoma (CD133 þ ) CSC-like cells (GSCs) 2 and targeted mouse GSC in vivo when armed with murine IL-12.
10 oHSV prevented tumor formation by neuroblastoma cells, which presumably reflects CSC targeting, 11 and lysed CD133 þ myogenically primitive rhabdomyosarcoma cells with CSC-like properties. 12 Engineered oHSVs that lyse GSC include those designed to have increased tumor penetration-for example, through the addition of an endoangio fusion gene (endostatin and angiostatin are angiogenesis inhibitors) or a chondroitinase adenosine triphosphate-binding cassette that removes the chondroitin sulfate from the tumor extracellular matrix proteoglycans. The latter oHSV spread throughout the glioma spheroids more efficiently than does the unmodified virus, and had enhanced replication and anti-tumor activity in vivo. [13] [14] [15] A multimutated oHSV, MG18L (Us3 and R1-negative), replicated well in GSC and synergized with the PI3K/Akt pathway inhibitors in killing CSCs through enhanced apoptosis, 16 and an oHSV containing the expression cassette for human granulocyte macrophage colony stimulating factor lysed doxorubicinenriched, ALDH (br) mouse breast CSC. 17 As virus replication is optimal in highly proliferating cells, it is becoming increasingly evident that the ability to induce programmed cell death (PCD) increases the therapeutic potential of the oncolytic viruses for CSC, which are largely quiescent cells. 6, [18] [19] [20] However, the contribution of the tumor cell type to CSC lysis and the ability of the virus mutants to override such potential limitations, if any, are still poorly understood.
DPK is an HSV-2 mutant that is only deleted in the R1 protein kinase domain (known as ICP10PK), which is not conserved in HSV-1. ICP10PK activates the Ras signaling pathways and is required for virus growth in slowly replicating normal cells, which unlike tumor cells have low levels of Ras activity. 21, 22 The loss of ICP10PK imparts tumor selectivity and favors virus induction of multiple death pathways, 18 thereby presumably increasing the clinical efficacy of DPK as an oncolytic agent. 19, 20 DPK is therapeutically promising because, in addition to being safe in intracranially and intraperitoneally injected animals, 18, 23, 24 it was well tolerated in phase I/II human clinical trials. 25 We have previously shown that DPK has strong in vivo oncolytic activity for melanoma, with xenograft-bearing animals remaining tumor-free for at least 1 year after treatment. 18 Whereas this implies that CSCs are not resistant to DPK, their lysis has not been documented and the role of virus-induced PCD pathways and tumor cell type, if any, are still poorly understood. These questions are clinically relevant because some pathways that may function in cell death, notably autophagy, are critically involved in maintaining normal physiological processes that counteract oncolytic activity in the CSCs. 26 
RESULTS
DPK lyses CSC-enriched breast cancer and melanoma cultures Two series of experiments were performed in order to examine the ability of DPK to lyse cells with CSC-like properties. In the first series of experiments, we used breast cancer (HS578T) and melanoma (A2058 and A375) cells grown as 3-dimensional (3D) multicellular tumor spheroids. These cultures include a gradient of proliferating cells similar to those found in tumor avascular microregions; they reflect the tumor microenvironment and are often used as in vitro surrogates of tumorigenesis. 5, [27] [28] [29] [30] Although the heterogeneity of CSC phenotypic markers is being increasingly recognized, 5, 6, 31 Figure 1S ). The 3D cultures were infected with DPK (multiplicity of infection (moi) ¼ 1) or mock-infected with phosphate-buffered saline (PBS) and examined for cell death by regular microscopy and staining with the cell death dye propidium iodide (PI) followed by flow cytometry (FCM). The DPK, but not mockinfected, spheroids, were largely reduced to debris ( Figure 1a) and most of the cells were stained with PI, confirming cell death (Figure 1b) .
In the second series of experiments, we examined the ability of DPK to prevent growth under 3D conditions that include spheroid growth and colony formation in soft agar. 2D cultures of HS578T, A2058 and A375 cells were infected with DPK (moi ¼ 1) or mockinfected with PBS and examined for spheroid and colony formation at 7 and 14 days post infection (p.i.), respectively. The results, expressed as spheroids or colonies/10 4 cells±s.d., indicate that DPK-infected cells do not grow under these conditions ( Figure 1c and Supplementary Material Supplementary Figure 2S) . Collectively, the data confirm that DPK lyses melanoma and breast cancer cultures that are CSC-enriched and abrogates 3D, CSC-like growth potential.
Low DPK titers lyse 3D spheroid cultures without resistance development Modest clinical efficacy of oncolytic virotherapy was attributed to poor tumor penetration due to low levels of virus replication and the presence of cell subpopulations with innate or acquired resistance. 3, 34 To examine the effect of virus titers and resistance on the ability of DPK to lyse 3D tumor-like cultures, spheroids were infected with DPK at different moi (0.1-10 pfu/cell) and examined for cell death by PI staining and by the failure to establish fresh spheroid cultures when subcultured in a virus-free medium. As shown in Figure 2 for A2058 cultures, virtually all the cells (95-99%) in the spheroids infected with 10 pfu/cell of DPK stained with PI at 48 h p.i. and the cells collected at 4-5 days p.i. failed to establish new cultures. Penetration was poorer in the cultures given 0.1 pfu/cell of DPK, with PI staining at 48 h p.i., seen only at the spheroid periphery. However, at 10 days p.i., the cultures were fully disrupted and X95% of the cells were stained with PI. Cultures established from the few remaining clusters of live (PI-negative) cells (Figure 2a arrow) were equally susceptible to DPK-mediated lysis and all the cells were lost through four iterations of infection with 0.1 pfu/cell. Similar results were obtained for A375 and HS578T cells. The data indicate that low titers of DPK can penetrate and lyse spheroids without resistance development.
DPK-infected 3D cultures evidence extensive cell lysis in the presence of low virus titers Deletions that impart tumor selectivity are known to reduce virus growth. [1] [2] [3] This was also shown for DPK, the titers of which in 2D cultures are 600-1000-fold lower than those of the wild-type virus (1-1.5 vs 1000-1200 pfu/cell, respectively). 18, 35 To examine whether this affects the ability of DPK to lyse CSC-enriched 3D cultures, HS578T and A2058 spheroids were infected with DPK (moi ¼ 1; 48 h) or mock-infected with PBS and stained in double immunofluorescence with antibodies to the respective CSC phenotypic markers (CD44/CD24 and CD271 for HS578T and A2058, respectively) and PI (to measure cell death). Co-staining with antibody to the major virus capsid protein VP5 and plaque forming assays were used to determine virus growth. Co-staining cells were counted in five randomly selected fields (X250 cells each) and the % calculated relative to the total number of imaged cells and virus titers were expressed as pfu/cell. The majority of the cells (total and expressing the respective CSC-associated phenotypes) in the DPK-infected cultures stained with PI (X80-92%; Figure 3a ), indicating that DPK induces extensive cell death in these 3D, CSC-enriched cultures. However, the maximal virus titers were only 1.6 pfu/cell ( Figure 3d ) and only one-third (X25-35%) of the cells (total or positive for CSC markers) co-stained with VP5 antibody (Figures 3b and c) . Collectively, the data suggest that virus-induced PCD pathways are likely to contribute to its oncolytic activity.
Calpain activation contributes to the DPK-mediated inhibition of 3D growth Activated PCD pathways increase the efficacy of oncolytic virotherapy. 6, [18] [19] [20] To better understand the contribution of death pathways to the oncolytic activity of DPK for CSCenriched 3D cultures, A2058, A375 and HS578T cells were mockinfected with PBS or infected with DPK (moi ¼ 1; 48 h) in the absence or presence of the calpain-specific inhibitor PD150606 (100 mM) or the pancaspase inhibitor ZVAD-fmk (20 mM) and assayed for growth in soft agar or spheroid culture. We focused on these two PCD pathways because they are involved in the DPKmediated killing of 2D melanoma cultures. 18 Results are expressed as % colonies or spheroids±s.d. calculated relative to the mockinfected cells (100%) and are shown in Figure 4 for A2058 colony formation. DPK-infected cells failed to grow in 3D culture, as also shown in Figure 1c . The calpain-specific inhibitor PD150606 restored 3D growth, but growth was not restored by treatment with the pancaspase inhibitor ZVAD-fmk, and the inhibitors did not affect the 3D growth of the mock-infected cultures. Similar results were obtained for spheroid growth and in all the cell types. The data indicate that calpain, but not caspase activation, contributes to the ability of DPK to inhibit 3D growth in both melanoma and breast cancer. Interestingly, however, the restoration of 3D growth was approximately twofold higher in melanoma than in breast cancer cultures (52.4 ± 6.2% for A2058, 67.8 ± 4.7% for A375 and 30.5 ± 3.8% for HS578T) (Figures 4a-c) , suggesting that the contribution of the death pathways to the oncolytic activity of DPK is malignant cell type specific.
Chloroquine (CQ) restores the 3D growth of DPK-infected melanoma, but not of breast cancer cells Having previously shown that DPK induces the expression of the autophagy protein beclin-1 in melanoma xenografts, 18 we wanted to know whether autophagy is also associated with the DPK-induced cell lysis seen in our 3D cultures. A2058, A375 and HS578T cells were mock-infected with PBS or infected with DPK (moi ¼ 1; 48 h) in the absence or presence of CQ (10 mM), which is an established autophagy inhibitor, 36, 37 and assayed for growth in soft agar or under spheroid conditions. CQ did not affect the 3D growth potential of the uninfected cultures, but it rescued the 3D growth of the DPK-infected melanoma cells. and WI-38 cells were infected with DPK (moi ¼ 1), examined for virus growth in serum-free medium and virus titers were determined by plaque assay. Results are expressed as mean pfu/cell (burst size). DPK is growth restricted in A2058 and HS578T cells and does not grow in WI-38 cells, as previously described.
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Rescue was cell type-specific, being twofold higher in A375 than in A2058 melanoma cells (70.8±7.8% and 41.1±4.1%, respectively) and it was not seen in breast cancer (HS578T) cells (Figures 4a-c) . Cell type specificity is not due to differential modulation of virus replication, because replication was nearly identical in all cultures. This is shown in Figure 4d for A2058 cells, and similar results were obtained in A375 and HS578T cells (0.9-1.1 pfu/cell at 24 h p.i.). The data indicate that CQ, used at the concentration at which it is known to inhibit autophagy, 36, 37 restores the 3D growth potential of the DPK-infected melanoma cells, thereby associating the DPK-induced cell lysis with autophagy. However, a similar association was not seen for breast cancer cells.
DPK infection induces LC3-II accumulation but does not alter Atg5 expression in melanoma spheroids To further examine the relationship between DPK-induced cell lysis and autophagy, we asked whether infection induces autophagy markers. We focused on the membrane-bound phosphatidyl-ethanolamine-conjugated form of microtubuleassociated protein 1 light chain 3 (LC3II), which binds autophagosome membranes, and Atg5, which conjugates with Atg12 to generate an E3 ubiquitin ligase-like enzyme required for autophagy. Both of these are widely used markers to identify autophagy. [38] [39] [40] In the first series of experiments, protein extracts from A2058 and A375 spheroids mock-infected with PBS or infected with DPK (moi ¼ 1) were immunoblotted with LC3 antibody and examined for the conversion of LC3I to LC3II. The stripped blots were probed with antibody to actin (loading control) and the results were quantified by densitometric scanning. DPK caused a significant increase (34-fold) in the LC3-II/LC3-I ratio relative to that seen in the mock-infected cultures in both melanoma cultures. LC3-II increase was seen as early as 1 h p.i. and it was still present at 24 h p.i. (Figure 5a ). In the second series of experiments, A2058 spheroids were mock-infected or infected with DPK (moi ¼ 1; 24 h) in the absence or presence of CQ (10 mM) and protein extracts were immunoblotted with antibody to Atg5. Atg5 was strongly expressed in the mock-infected cultures and DPK did not alter its levels, which were similar to those seen in mock-infected cultures and in cultures infected with DPK in the presence of CQ (Figure 5b) . Collectively, the data indicate that DPK modulates some (that is, LC3II), but not other (that is, Atg5), markers of autophagy. p62/SQSTM1 is cleared from DPK-infected melanoma spheroids p62/SQSTM1 is a stress-inducible protein that interacts with LC3. It has a crucial role as an assembly factor for ubiquitinated proteins and organelles and is ultimately degraded by autophagy. 41 Having seen that DPK modulates some but not other autophagy markers, we wanted to better understand its effect on p62/SQSTM1, which also functions as a signaling hub in the life and death pathways and is implicated in tumorigenesis. [41] [42] [43] A2058 and A375 spheroids were mock-infected or infected with DPK in the absence or presence of CQ (10 mM) and immunoblotted with antibody to p62/SQSTM1. The blots were stripped and reblotted with antibody to GAPDH and the levels of p62/SQSTM1 determined by densitometric scanning and analyzed relative to GAPDH. As shown in Figure 5b for A2058 cells, p62/SQSTM1 was expressed in the mock, but not DPK-infected, cultures, indicating that DPK induces p62/SQSTM1 clearance. Significantly, however, expression was not restored by treatment of the infected cells with the autophagy inhibitor CQ (Figures 5b and c) , suggesting that the DPK-mediated clearance of p62/SQSTM1 is through a mechanism other than autophagy. Similar results were obtained for A375 spheroids. This is particularly relevant from the standpoint of virus oncolysis because, in addition to being implicated in tumorigenesis, 43 high levels of p62/SQSTM1 were also associated with significantly worse prognosis and tumor progression, at least in lung and breast cancer. 44, 45 DPK-mediated p62/SQSTM1 clearance is calpain-dependent To better understand the mechanism responsible for the clearance of p62/SQSTM1, duplicate spheroid cultures were infected with DPK (moi ¼ 1; 24 h) in the absence or presence of PD150606 (100 mM), and protein extracts were immunoblotted with antibody to p62/SQSTM1 followed by immunoblotting of the sequentially stripped blots with antibodies to the calpain regulatory subunit p28, the loss of which documents calpain activation, or apoptosis-inducing factor (AIF), which is an apoptosis-associated calpain target. 46 p62/SQSTM1 expression was fully restored in the PD150606-treated DPK-infected spheroid cultures, indicating that its clearance is calpaindependent (Figures 5b and c) . Indeed, DPK induced calpain activation as evidenced by (i) loss of the p28 regulatory subunit in DPK-infected cells and (ii) restored expression in infected cells treated with the calpain inhibitor PD150606 (Figures 5b and c) . The levels of AIF were similar under all conditions (Figures 5b and c) , indicating that calpain does not function at this level. Collectively, the data indicate that calpain-mediated p62/SQSTM1 degradation is a key contributor to the DPK oncolytic activity in CSC-enriched 3D melanoma cultures.
DISCUSSION
The salient feature of the data presented in this report is the finding that DPK has strong oncolytic activity in CSC-enriched melanoma and breast cancer 3D cultures that involves calpain activation and the clearance of p62/SQSTM1 in the melanoma cultures. The following comments seem pertinent with respect to these findings.
Direct studies of CSC lysis are relatively scant. oHSV, including those engineered to increase tumor penetration and virus spread, were shown to kill glioblastoma, neuroblastoma and rhabdomyosarcoma cells with CSC-like properties.
2,10-17 However, tumors appear to harbor multiple phenotypically and/or genetically distinct CSCs, 5, 6, 31 underscoring the therapeutic advantage of a virus that elicits the PCD pathways tailored to distinct cell types. DPK differs from most oHSV in that it is based on HSV-2 and is deleted in ICP10PK, which is not conserved in HSV-1, but it retains the replication-associated ICP34.5 and ribonucleotide reductase activities. 2, 7 ICP10PK activates the Ras signaling pathways and contributes to virus growth, such that its deletion enables tumor selectivity, reduces replicative potential and induces multiple PCD pathways. 18, 21, 22, 24, 35 The ICP10PK-deleted virus, DPK, was well tolerated in phase I/II human clinical trials 25 and it has strong in vivo oncolytic activity in melanoma, with xenograft-bearing animals remaining tumor-free for at least 1 year after treatment. 18 Although this implies that CSCs are not resistant to DPK, their lysis remains to be documented.
We studied 3D melanoma and breast cancer cultures that are enriched in the widely distributed CSC phenotypic markers CD44 þ
CD24
À /low (breast cancer) and CD271 (melanoma). 5, [31] [32] [33] 47, 48 These cultures are enriched for slow cycling pluripotent cells with enhanced tumorigenicity and drug resistance and mimic in vivo tumors in their microenvironment, pH and oxygen gradients, growth factor distribution and interaction with the extracellular matrix. [27] [28] [29] [30] They are known to resist oncolytic virotherapy owing to reduced virus penetration and spread. [13] [14] [15] Our data indicate that DPK effectively penetrates 3D spheroid cultures even when given at the very low titer of 0.1 pfu/cell and it lyses most of the cells by 10 days p.i. The few cells that survived this treatment were equally susceptible to lysis by these low virus titers and the entire culture was completely eradicated through four cycles of infection, indicative of a fundamental lack of resistance to DPK lysis. Resistance development is a major therapeutic challenge 2, 34 and its absence is clinically relevant, because multiple injections are typically required during a treatment regimen. While these and previous 18 findings suggest that DPK has effective tumor penetration, the potential contribution of density, hypoxic regions, intratumoral heterogeneity, stromal tissue barriers and blood flow remains to be determined and studies on cancer-initiating cells from actual tumors are still needed.
In addition to lysing CSC-enriched cultures, DPK inhibited the 3D growth potential of both melanoma and breast cancer cells, as measured by spheroid and agarose colony formation. Growth was restored by treatment with PD150606, which is a cellpermeable, non-competitive and selective inhibitor of both calpain-1 and -2 that is directed towards the calpain Ca 2 þ binding sites. The calpain specificity of PD150606 is fully established and it was used at independently established doses. 18, 46, [49] [50] [51] Growth was not restored by PD145305, which is an inactive analog of PD150606 (data not shown). Together with the findings that (i) DPK caused the loss of the p28 calpain regulatory subunit and (ii) PD150606 restored its expression, the data indicate that calpain activation contributes to the oncolytic activity of DPK in the 3D melanoma and breast cancer cultures. Calpains are Ca 2 þ -activated non-lysosomal cysteine proteases that have paradoxical functions in the perturbed cancer apoptotic pathways. Calpain activity was implicated in the prosurvival activities of the tumor suppressor protein p53 and nuclear factor-kB, but it was also shown to cause cell death by inducing the collapse of the mitochondrial membrane potential (DC m ) and the induction of both caspase-dependent and independent (AIF-dependent) death pathways. 46, 51 Interestingly, the pancaspase inhibitor ZVAD-fmk did not restore 3D spheroid/ agarose growth, although caspase activation is involved in the oncolytic activity of DPK in 2D melanoma cultures, 18 potentially reflecting increased CSC expression of anti-apoptotic proteins (that is, Bcl-2 and survivin). 52 Autophagy has been implicated in maintaining normal physiological processes, particularly in CSC, where it enables survival in the tumor microenvironment, 26 and it contributes to breast cancer tumorigenicity. 53 However, a growing body of evidence supports the contribution of bona fide autophagic cell death to various pathological conditions, with various factors governing the cellular decision to die by autophagy. 54 In cancer, autophagy can be proor anti-tumorigenic depending on the specific tissue and tumor stage. 55 Currently available data for melanoma support both protective and cytotoxic activities, albeit by still poorly understood mechanisms. 56 We found that CQ, used at a dose at which it is known to inhibit autophagy, restored the 3D growth of DPKinfected melanoma, but not breast cancer cultures, providing a measure of specificity. In addition, the DPK-infected melanoma spheroids had increased levels of LC3-II accompanied by p62/ SQSTM1 clearance, an established signature of autophagy. 41, 42 However, the relationship between DPK and autophagy is confounded by the finding that DPK did not alter the expression of Atg5, which has a critical role in autophagy activation by participating in two essential pathways-that is, Atg12-Atg5 conjugation and LC3 lipidation. [38] [39] [40] Moreover, the expression of p62/SQSTM1 was not restored by CQ but rather by the calpain inhibitor PD150606. A possible interpretation of our findings is that the observed LC3-II accumulation reflects a residual effort by the cells to survive DPK-induced cell death. However, implicit in this interpretation is the conclusion that the ability of CQ to restore 3D growth is through a prosurvival function other than autophagy that is melanoma-specific. While such a function remains elusive, and discounting the possible contribution of dose, it may be important to point out that CQ (used at a dose fivefold higher than ours), was recently shown to have melanoma-specific BH3-protein-dependent activity. 57 Further studies are needed in order to test this interpretation for DPK and to better elucidate the contribution of autophagy, if any, to its oncolytic activity.
Notwithstanding, to the extent of our knowledge, ours is the first report that calpain activation induces anti-tumor activity through p62/SQSTM1 degradation. Indeed, p62/SQSTM1 was previously implicated in Ras-induced tumorigenesis and its loss inhibited Ras-controlled transformation, apparently through ROSinduced cell death. 58 Moreover, high levels of p62/SQSTM1 were associated with worse prognosis and tumor progression in breast and non-small-cell lung cancer. [43] [44] [45] Although the potential contribution of other death pathways and inflammatory signals 18 to the ability of DPK to lyse breast cancer spheroids remains unclear, our data underscore the importance of the tumor cell type in the selection of an effective oncolytic platform and highlight the versatility of DPK.
MATERIALS AND METHODS

Cells and virus
A2058 and A375 melanoma cells were obtained from the American Type Culture Collection (Manassas, VA, USA). HS578T breast cancer cells were a gift from Dr Angela Brodie (University of Maryland, Baltimore, MD, USA).
They were grown in adherent monolayers cultures in Dulbeco modified Eagle's medium ((DMEM), Invitrogen, Carlsbad, CA, USA) supplemented with L-glutamine (4 mM) and 10% fetal bovine serum (FBS, Gemini Bioproducts, Calabasos, CA, USA). WI-38 cells (normal human embryonic lung fibroblasts) are an expansion from passage 9 and have a limited lifespan of 50 population doublings. They were cultured in minimal essential medium with Earle's salts, 10% fetal bovine serum, 1 mm sodium pyruvate and 0.1 mm nonessential amino acids. The generation and properties of the HSV-2 mutant DPK that is deleted in the kinase domain of the large subunit of ribonucleotide reductase (R1, also known as ICP10) were previously described. 18, [21] [22] [23] [24] 46 Antibodies, pharmacological inhibitors and chemical reagents
The generation and specificity of the rabbit polyclonal antibody to ICP10, which recognizes an epitope that is retained by both ICP10 and the PK-deleted p95 protein, have been previously described. 18, [21] [22] [23] [24] 46 The following antibodies were purchased and used according to the manufacturer's instructions. FITC-conjugated anti-CD20 and APCconjugated anti-CD133 antibodies were from Miltenyi Biotec (Auburn, CA, USA). FITC-conjugated anti-CD24, APC-conjugated anti-CD44, APCconjugated anti-ABCG2, FITC-conjugated IgG1 isotype, APC-conjugated IgG2b isotype and APC-conjugated anti-mouse antibodies were from BD Biosciences (San Jose, CA, USA). Antibodies to AIF, LC3, calpain and GAPDH were from Santa Cruz Biotechnologies (Santa Cruz, CA, USA); antibodies to p62 and ATG5 were from Cell Signaling Technologies (Danvers, MA, USA); and antibody to VP5 was from Virusys (Taneytown, MD, USA). Alexafluor 594-conjugated anti-mouse, Alexafluor 488-conjugated anti-rabbit antibody and SlowFade Gold (with 4',6-diamidino-2-phenylindole (DAPI)) mounting medium were from Invitrogen. The calpain inhibitor PD150606 from Calbiochem (La Jolla, CA, USA) and the pancaspase inhibitor benzyloxcarbonyl-Val-Ala-Asp-fluormethyl ketone (zVAD-fmk) from Promega (Madison, WI, USA). CQ, PI, low melting point agarose and Tween 20 were from Sigma-Aldrich (Carlsbad, CA, USA) and Accutase was from Innovative Cell Technologies, Inc (San Diego, CA, USA). All the inhibitors were selected for their target specificity and used at doses recommended by the manufacturer and confirmed in the literature. 18, 47, [49] [50] [51] Anchorage-independent growth Anchorage-independent growth was assessed by both spheroid and soft agar growth assays. For spheroid growth, cells were suspended in serumfree DMEM supplemented with 20 ng/ml basic fibroblast growth factor (bFGF, R&D Systems, Minneapolis, MN, USA) and 20 ng/ml epidermal growth factor (EGF, R&D Systems), plated (1 Â 10 4 /well) onto ultra-low attachment plates (Corning, Corning, NY, USA) and grown at 37 1C for 7 days. The assay was performed in triplicate, spheroids (X500 mm in diameter) were counted and the results are expressed as number of spheroids/10 4 cells ± s.d. Soft agar colonies were grown as previously described. 59 Briefly, cells (500 or 5000/well) were suspended in 0.3% low melting temperature agarose in 1 Â DMEM and overlaid onto 0.6% agarose in 1 Â DMEM in 24-well plates. The solidified agarose-cell mixture was overlaid with 1 Â DMEM, the plates were incubated at 37 1C for 14 days, and colonies (defined asX50 mm diameter) were counted. The assay was performed in triplicate and the results are expressed as number of colonies/10 4 cells ± s.d.
Virus infection of spheroid cultures
Spheroid cultures were infected either as intact 3D cultures or after they were dissociated into single cell suspensions by treatment with accutase (37 1C, 5 min). To estimate the (moi ¼ pfu/cell) for the intact spheroid cultures, duplicate representative cultures were dissociated before cell counting. For all cultures, virus was adsorbed in adsorption medium (PBS with 0.2% glucose and 0.2% bovine serum albumin) for 1 h at 4 1C (synchronized adsorption) and removed by centrifugation (800-1500 rpm; 5-10 min) prior to reincubation at 37 1C.
Cell death
Staining with PI, a cell impermeant red fluorescent nuclear dye used to determine cell death, was performed according to the manufacturer's instructions and visualized by microscopy using a Nikon E4100 fluorescent microscope (Melville, NY, USA) that utilizes bright-field and a Texas Red (540-580 nm) cube. Stained cells were counted in five randomly selected Calpain-autophagy interaction in DPK oncolytic activity A Colunga et al 3 mm 2 fields (X250 cells each), and the % positive cells was calculated relative to total number of cells imaged by phase contrast microscopy. 23, 24, 46 Immunofluorescence and FCM Immunofluorescent staining was as previously described. 23, 24, 46 Briefly, cells were fixed with 4% paraformaldehyde overnight at 4 1C, blocked with 5% normal goat serum and 5% bovine serum albumin (30 min, room temperature) and incubated with primary antibody overnight at 4 1C. They were washed in PBS with 0.1% Tween 20, exposed to fluorochrome-labeled secondary antibodies (37 1C, 1 h) and mounted in Vectashield with DAPI (Vector Laboratories, Burlingame, CA, USA). Slides were visualized with an Olympus BX50 fluorescence microscope (Center Valley, PA, USA) utilizing FITC (330-380 nm), UV (for DAPI) (465-495 nm) and Texas red (540-580 nm) cubes. Stained cells were counted in five randomly selected 3 mm 2 fields (X250 cells each) and the percentage of positive cells was calculated relative to total number of cells imaged by DAPI. FCM was carried out as previously described. 60 Briefly, washed cells were resuspended (10 6 cells/tube) in FCM buffer (2% fetal bovine serum in 1 Â PBS) and incubated (10 min.) at room temperature with human Fcbinding inhibitor (eBiosciences; San Diego, CA, USA). This was followed by incubation (20 min. 4 1C in the dark) with primary antibodies followed by the corresponding secondary antibodies (20 min, room temperature), and the washed cells were fixed with 1% paraformaldehyde. Isotype-matched APC and FITC-conjugated antibodies were used as controls. Data were acquired using a LSRII benchtop flow cytometer (BD Biosciences) and analyzed with the FlowJo software package (Tree Star, Ashland, OR, USA).
Immunoblotting
